Gyre Therapeutics (GYRE) Sidoti Micro-Cap Virtual Conference summary

Key presentations and strategic updates

• Highlighted three approved commercial drugs: Pirfenidone, Nintedanib (generic acquired in May 2024), and Avatrombopag, strengthening market position and financial sustainability.

• Emphasized differentiation through a proven track record in anti-fibrotic drug development and a focus on chronic inflammation pathways, targeting multiple organ diseases.

• Lead candidate F351 (Hydronidone), a Pirfenidone derivative, is in pivotal phase III trials for HBV-associated liver fibrosis in China, with top-line results expected early 2025.

• U.S. phase II trial for F351 to be filed by end of 2024, with plans to expand into MASH/NASH-associated liver fibrosis.

• Pipeline includes additional candidates: IF-523 (caspase inhibitor for acute liver injury), F230 (pulmonary arterial hypertension), and F528 (chronic obstructive pulmonary disease).

Risk management and financial outlook

• Commercial, clinical, and regulatory risks are mitigated by a diversified product portfolio and experienced team.

• $112 million in 2023 revenue from China sales; $44 million in cash and investments, with ongoing profitability supporting operations.

• U.S. expansion will require additional funding, especially for phase III trials; partnerships and non-dilutive financing are being explored.

• Strong sales network in China (500+ staff, expanding), with two-way collaboration opportunities for commercialization in and outside China.

• Recent Nasdaq listing and inclusion in Russell indices have increased visibility, though low liquidity and concentrated ownership contribute to share price volatility.

Clinical and market insights

• F351 designed for better safety and patent protection compared to Pirfenidone, aiming for global reach.

• Phase II data for F351 show significant benefit in fibrosis improvement and favorable toxicity profile.

• NASH and liver fibrosis markets are large and growing, with potential for multi-billion dollar annual sales.

• Current focus for F351 is HBV-associated liver fibrosis, with future potential in MASH/NASH and possibly pulmonary fibrosis.

• Commercialization of two additional drugs expected soon, further supporting financial sustainability.